GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Medx Health Corp (OTCPK:MDXHF) » Definitions » Altman Z-Score

MDXHF (Medx Health) Altman Z-Score : -102.40 (As of Mar. 25, 2025)


View and export this data going back to 2013. Start your Free Trial

What is Medx Health Altman Z-Score?

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

Warning Sign:

Altman Z-score of -102.5 is in distress zone. This implies bankruptcy possibility in the next two years.

Medx Health has a Altman Z-Score of -102.40, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for Medx Health's Altman Z-Score or its related term are showing as below:

MDXHF' s Altman Z-Score Range Over the Past 10 Years
Min: -131.33   Med: -77.75   Max: -11.58
Current: -102.5

During the past 13 years, Medx Health's highest Altman Z-Score was -11.58. The lowest was -131.33. And the median was -77.75.


Medx Health Altman Z-Score Historical Data

The historical data trend for Medx Health's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medx Health Altman Z-Score Chart

Medx Health Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Altman Z-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -131.33 -80.75 -99.07 -117.32 -123.96

Medx Health Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Altman Z-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -115.50 -123.96 -124.63 -104.33 -102.50

Competitive Comparison of Medx Health's Altman Z-Score

For the Medical Devices subindustry, Medx Health's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medx Health's Altman Z-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Medx Health's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where Medx Health's Altman Z-Score falls into.



Medx Health Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Medx Health's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*-9.1592+1.4*-60.9258+3.3*-2.2844+0.6*1.6744+1.0*0.4189
=-102.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Sep. 2024:
Total Assets was $0.65 Mil.
Total Current Assets was $0.61 Mil.
Total Current Liabilities was $6.54 Mil.
Retained Earnings was $-39.42 Mil.
Pre-Tax Income was -0.512 + -0.676 + -0.685 + -0.449 = $-2.32 Mil.
Interest Expense was -0.153 + -0.139 + -0.13 + -0.422 = $-0.84 Mil.
Revenue was 0.067 + 0.076 + 0.079 + 0.049 = $0.27 Mil.
Market Cap (Today) was $12.17 Mil.
Total Liabilities was $7.27 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(0.609 - 6.535)/0.647
=-9.1592

X2=Retained Earnings/Total Assets
=-39.419/0.647
=-60.9258

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-2.322 - -0.844)/0.647
=-2.2844

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=12.173/7.27
=1.6744

X5=Revenue/Total Assets
=0.271/0.647
=0.4189

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

Medx Health has a Altman Z-Score of -102.40 indicating it is in Distress Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.


Medx Health  (OTCPK:MDXHF) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


Medx Health Altman Z-Score Related Terms

Thank you for viewing the detailed overview of Medx Health's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Medx Health Business Description

Traded in Other Exchanges
Address
1495 Bonhill Road, Unit 1, Mississauga, ON, CAN, L5T 1M2
Medx Health Corp is engaged in the development, manufacturing, and marketing of skin-related screening tools and phototherapy devices for pain relief and tissue repair. Its two main product lines are; SIAscopy, a medical device technology that is used to scan skin for suspicious moles and lesions; and Phototherapeutic medical devices, which use light energy in lower-level laser and LED to provide effective treatment of pain and tissue damage in the rehabilitation market. It derives key revenue from the sale of Phototherapeutic lasers. The company sells its products internationally, of which prime revenue is generated in Canada and the United States.